Back to top
Read MoreHide Full Article

Monday, April 28, 2014

Pre-open sentiment remains positive today, though it’s hard to pin the favorable mood on anything specific. We have a number of major deal announcements in the pharma, cable, and industrial space today and remain in peak earnings season with more than 130 S&P 500 companies reporting results this week. Importantly, this is a big weak on the economic calendar, with a Fed meeting and the monthly jobs report coming out.

The corporate headlines today are dominated by the mega Pfizer (PFE - Free Report) – AstraZeneca (AZN - Free Report) deal and the fight between General Electric (GE - Free Report) and Germany’s Siemans about the French firm Alstom’s energy assets. Deal activity has heated up lately, likely indicating greater confidence among management teams about the business outlook. On the flip side, accelerated M&A activities may also be pointing towards lack of ‘organic’ growth opportunities, prompting management teams to buy growth instead of producing it internally.

We have been seeing the growth challenge on the earnings front for some time and the ongoing Q1 earnings season is further highlighting the issue. With more than half of the Q1 earnings season now behind us, earnings results are a tad bit better relative to the extremely low level to which expectations had fallen ahead of the start of the reporting season. But there is not much  growth, most companies are missing top-line estimates and guidance still remains on the weak side, causing estimates for the current quarter (2014 Q2) to come down.

Including this morning’s earnings reports through 7:30 CST, we now have Q1 results from 245 S&P 500 members that combined account for almost 61% of the index’s total market capitalization. Total earnings for these 245 companies are up +1.9% from the same period last year on +3.8% higher revenues, with 66.8% beating EPS estimates and 49.8% coming out with positive revenue surprises. Compared to other recent quarters, the earnings growth performance from these 245 companies is on the weak side (largely due to the Finance sector), revenue growth and earnings beat ratios are along historical levels, while the revenue beat ratios are tracking lower.

Bottom line, there is nothing exciting on offer in this earnings season – there is not much growth and the outlook for the coming quarters is cloudy. The only silver lining is that Q1 earnings growth is turning out to be somewhat better relative to the lowered expectations. And what  matters to the stock market is how results compare relative to expectations, not the absolute level of performance.

Sheraz Mian
Director of Research

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

The full Ahead Of Wall Street article

Astrazeneca PLC (AZN) - free report >>

Pfizer, Inc. (PFE) - free report >>

General Electric Company (GE) - free report >>

More from Zacks Ahead of Wall Street

You May Like